Certolizumab pegol in the treatment of rheumatoid arthritis: A comprehensive review of its clinical efficacy and safety

Rheumatology

Volumn 50, Issue 2, 2011, Pages 261-270

  Mease, Philip J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Certolizumab pegol; Methotrexate; Monotherapy; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL CORTEX ADENOMA; B CELL LYMPHOMA; BACTERIAL ARTHRITIS; BASAL CELL CARCINOMA; BLADDER CANCER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COLON CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; ESOPHAGUS CARCINOMA; FATIGUE; FEMUR FRACTURE; FUNCTIONAL ASSESSMENT; HEADACHE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INJECTION SITE PAIN; JOINT INJURY; LEISURE; LIVER CANCER; MENORRHAGIA; MONOTHERAPY; OUTCOME ASSESSMENT; PAIN; PAPILLOMA; PNEUMONIA; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SELF REPORT; SHOCK; SIDE EFFECT; SINUSITIS; SOCIAL BEHAVIOR; TESTIS CANCER; THYROID CANCER; TONGUE CANCER; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UREA BLOOD LEVEL; URINARY TRACT INFECTION; UTERUS CANCER;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; METHOTREXATE; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78751680650     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq285     Document Type: Review

References (28)

1. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408.
2. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348:36-41.
3. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32.
4. Keystone E, van der Heijde D, Mason D et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
5. Smolen JS, Landewe R, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
6. Fleischmann R, Vencovsky J, van Vollenhoven R et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
7. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Keystone E, Fleischmann R, Smolen J et al. The efficacy of certolizumab pegol added to methotrexate is sustained over 2 years in the treatment of rheumatoid arthritis. Arthritis Rheum 2009;60(Suppl.):S622.
9. Ware JE, Kosinski M, Keller SK. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: New England Medical Center, The Health Institute, 1994.
10. Tack BB. Self-reported fatigue in rheumatoid arthritis. A pilot study. Arthritis Care Res 1990;3:154-7.
11. Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9: 105-21.
12. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
13. Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
14. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13(Suppl. 9):S237-51.
15. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
16. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
17. Wells G, Li T, Maxwell L, MacLean R, Tugwell P. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007;34:280-9.
18. Strand V, Keininger DL, Tahiri-Fitzgerald E. Certolizumab pegol results in clinically meaningful improvements in physical function and health-related quality of life in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum 2007;56(Suppl.):393.
19. CIMZIA. [summary of product characteristics]. Bruxelles, Belgium: UCB Pharma, SA, 2009.
20. Strand V, Brown M, Purcaru O. Certolizumab pegol monotherapy improves productivity in patients with active rheumatoid arthritis: results from a phase III randomized controlled trial. Ann Rheum Dis 2007;66(Suppl. II):274.
21. Mease P. Certolizumab pegol for rheumatoid arthritis: effective in combination with methotrexate or as monotherapy. Int J Clin Rheumatol 2009;4:253-66.
22. Schiff M, Keininger DL. Certolizumab pegol added onto methotrexate improves physical function and reduces pain in patients with rheumatoid arthritis who have an incomplete response to methotrexate: data from RAPID 2. Ann Rheum Dis 2007;66(Suppl. II):187.
23. Strand V, Fleischmann R, Kvien TK et al. Certolizumab pegol (CZP) added to methotrexate (MTX) provides lasting improvements in patient-reported outcomes (PROs) over years. Arthritis Rheum 2009;60(Suppl.):S636.
24. Strand V, Keininger DL, Tahari-Fitzgerald E, Fleischmann R. Certolizumab pegol monotherapy 400mg every 4 weeks improves health-related quality of life and relieves fatigue in patients with rheumatoid arthritis who have previously failed DMARD therapy. Ann Rheum Dis 2007;66(Suppl. III):188.
25. Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 2009;11:R73.
26. Kavanaugh A, Smolen J, Emery P et al. Certolizumab pegol with methotrexate improves home and workplace productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res 2009;61:1592-600.
27. Hazes J, Purcaru O, Coteur G, Mease P. Increased productivity at work and in household duties associated with reduced fatigue and improved physical function in RA patients. Ann Rheum Dis 2008;67(Suppl. II):79.
28. Westhovens R, Purcaru O. Certolizumab pegol in combination with methotrexate or as monotherapy shows cumulative gains over time in work and home productivity in patients with active rheumatoid arthritis. In: The 13th Belgian Congress on Rheumatology, September 23-25, 2009, Mechelen, Belgium.